Abstract | BACKGROUND: METHODS: RESULTS: p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes. CONCLUSION: p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy.
|
Authors | Akin Atmaca, Claudia Pauligk, Kristina Steinmetz, Hans-Michael Altmannsberger, Elke Jäger, Salah-Eddin Al-Batran |
Journal | Oncology
(Oncology)
Vol. 80
Issue 1-2
Pg. 130-4
( 2011)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 21677458
(Publication Type: Journal Article)
|
Copyright | Copyright © 2011 S. Karger AG, Basel. |
Chemical References |
- MIB1 ligase, human
- Ubiquitin-Protein Ligases
- MAPK1 protein, human
- Mitogen-Activated Protein Kinase 1
- Mitogen-Activated Protein Kinase 3
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cell Line, Tumor
- Cell Proliferation
- Disease-Free Survival
- Humans
- Immunochemistry
- Kaplan-Meier Estimate
- Mitogen-Activated Protein Kinase 1
(metabolism)
- Mitogen-Activated Protein Kinase 3
(metabolism)
- Phosphorylation
- Predictive Value of Tests
- Prognosis
- Proportional Hazards Models
- Retrospective Studies
- Stomach Neoplasms
(drug therapy, metabolism, mortality)
- Survival Rate
- Treatment Outcome
- Ubiquitin-Protein Ligases
(metabolism)
|